MIRANDA tozorakimab COPD study
A Phase 3 study that evaluated tozorakimab in adults with symptomatic COPD and prior exacerbations.
Study overview
MIRANDA is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating subcutaneous tozorakimab in adults with symptomatic chronic obstructive pulmonary disease, commonly called COPD, and a recent history of moderate or severe exacerbations. Participants continue optimized inhaled maintenance therapy permitted by the protocol. The registered study is active but not recruiting, so this page provides educational information and does not confirm that new participants can enroll.
What the research examines
Researchers are evaluating whether tozorakimab affects the rate of COPD exacerbations and are monitoring lung function, respiratory symptoms, health status, safety, and tolerability. Study procedures may include breathing tests, examinations, questionnaires, blood testing, medication review, injections, and monitoring for infections or other adverse events. Randomization assigns study treatment, and double-blinding limits knowledge of whether tozorakimab or placebo is given during the controlled period. Tozorakimab is investigational, and its benefits and risks for COPD are not fully established.
Asking about participation
Eligibility for this protocol may depend on age, confirmed COPD, symptom burden, smoking history, recent exacerbations, inhaled therapy, lung-function results, other respiratory diagnoses, infections, medications, and general health. The official protocol and qualified study clinicians determine eligibility. Since the registry lists the study as not recruiting, staff can only explain the record or discuss whether separate research opportunities exist. Participation in any study is voluntary and requires its own screening and informed-consent process.
Continue routine COPD care and follow an existing clinician’s emergency plan; severe breathing difficulty may require emergency services. For a general research inquiry, use the secure information-request form. Do not include medical records, pulmonary test results, insurance information, or sensitive health details in the initial submission.